Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drug Metabolism and Bioanalysis Letters is not currently indexed in Scopus. Its Scopus CiteScore is 2.2, quartile Q3. It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 2949-6810Verify ISSN ↗2949-6829Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmaceutical Science | 114 / 191 | 40th | Q3 |
| Biochemistry (medical) | 48 / 78 | 39th | Q3 |
| Pharmacology (medical) | 178 / 278 | 36th | Q3 |
| Clinical Biochemistry | 98 / 124 | 21st | Q4 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
No — it was previously covered by Scopus but its coverage is now inactive/discontinued (2022–present).
Drug Metabolism and Bioanalysis Letters is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 2.2, quartile Q3, 40th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.286, quartile Q3, with an H-index of 36.
Drug Metabolism and Bioanalysis Letters is published by Bentham Science Publishers. Its print ISSN is 2949-6810 and its online ISSN is 2949-6829.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Drug Metabolism and Bioanalysis Letters has an h-index of 8 and a 2-year mean of 1.03 citations per paper (OpenAlex). Its Scopus CiteScore is 2.2, quartile Q3.
Drug Metabolism and Bioanalysis Letters published 20 papers in 2025; its busiest recent year was 2022 with 23. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. Updated 2026-10-14.
In its latest 59 research articles (2021–2025), authors are most often from India (61.9%), Japan (8.5%) and United States (5.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Inactive — coverage ended 2026. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.